 Hesham Eissa
Concepts (81)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Severe Combined Immunodeficiency | 6 | 2023 | 19 | 1.910 |
Why?
| | Hematopoietic Stem Cell Transplantation | 11 | 2023 | 519 | 1.860 |
Why?
| | Graft vs Host Disease | 4 | 2023 | 212 | 0.680 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 2022 | 61 | 0.380 |
Why?
| | Cancer Survivors | 2 | 2021 | 205 | 0.270 |
Why?
| | Transplantation Conditioning | 2 | 2023 | 149 | 0.250 |
Why?
| | Canada | 1 | 2023 | 320 | 0.200 |
Why?
| | Lymphopenia | 1 | 2022 | 49 | 0.200 |
Why?
| | Agammaglobulinemia | 1 | 2022 | 30 | 0.200 |
Why?
| | Pleural Effusion | 1 | 2021 | 46 | 0.190 |
Why?
| | Hypogonadism | 1 | 2021 | 75 | 0.190 |
Why?
| | Infertility | 1 | 2021 | 45 | 0.190 |
Why?
| | Immune Reconstitution | 1 | 2021 | 6 | 0.180 |
Why?
| | Testicular Neoplasms | 1 | 2021 | 96 | 0.170 |
Why?
| | Renal Insufficiency | 1 | 2021 | 137 | 0.170 |
Why?
| | Interleukin-2 Receptor beta Subunit | 1 | 2019 | 18 | 0.160 |
Why?
| | Hematologic Neoplasms | 1 | 2020 | 136 | 0.150 |
Why?
| | Cognition Disorders | 1 | 2022 | 476 | 0.150 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 251 | 0.150 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 286 | 0.150 |
Why?
| | Incidence | 1 | 2023 | 2314 | 0.140 |
Why?
| | Killer Cells, Natural | 1 | 2019 | 380 | 0.130 |
Why?
| | Quality of Life | 3 | 2022 | 2343 | 0.130 |
Why?
| | Vaccines | 1 | 2021 | 375 | 0.130 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2021 | 533 | 0.120 |
Why?
| | Child | 5 | 2023 | 18400 | 0.110 |
Why?
| | Retrospective Studies | 3 | 2023 | 12521 | 0.100 |
Why?
| | Humans | 14 | 2023 | 114043 | 0.100 |
Why?
| | T-Lymphocytes | 1 | 2019 | 1735 | 0.090 |
Why?
| | Bone Marrow | 2 | 2022 | 243 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2021 | 1875 | 0.090 |
Why?
| | Heart Failure | 1 | 2021 | 1958 | 0.080 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2022 | 615 | 0.080 |
Why?
| | Mutation | 1 | 2019 | 3338 | 0.080 |
Why?
| | Infant, Newborn | 3 | 2023 | 5038 | 0.070 |
Why?
| | Neoplasms | 1 | 2021 | 2086 | 0.070 |
Why?
| | Adenosine Deaminase | 1 | 2022 | 24 | 0.050 |
Why?
| | Neonatal Screening | 1 | 2023 | 151 | 0.050 |
Why?
| | Thymus Gland | 1 | 2022 | 296 | 0.050 |
Why?
| | Immunologic Tests | 1 | 2021 | 16 | 0.050 |
Why?
| | Blood Cell Count | 1 | 2021 | 50 | 0.050 |
Why?
| | Transplant Recipients | 1 | 2022 | 136 | 0.040 |
Why?
| | Proportional Hazards Models | 1 | 2023 | 1078 | 0.040 |
Why?
| | Adaptive Immunity | 1 | 2021 | 154 | 0.040 |
Why?
| | Infant | 2 | 2022 | 7943 | 0.040 |
Why?
| | Cell Compartmentation | 1 | 2019 | 51 | 0.040 |
Why?
| | Homeodomain Proteins | 1 | 2022 | 463 | 0.040 |
Why?
| | Spleen | 1 | 2021 | 485 | 0.040 |
Why?
| | Interleukin-15 | 1 | 2019 | 74 | 0.040 |
Why?
| | Homozygote | 1 | 2019 | 187 | 0.040 |
Why?
| | Immunophenotyping | 1 | 2019 | 274 | 0.040 |
Why?
| | Siblings | 1 | 2019 | 220 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2022 | 926 | 0.040 |
Why?
| | Interleukin-2 | 1 | 2019 | 413 | 0.040 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2022 | 686 | 0.040 |
Why?
| | Cytomegalovirus Infections | 1 | 2019 | 180 | 0.030 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2022 | 959 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2023 | 2384 | 0.030 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2021 | 850 | 0.030 |
Why?
| | Male | 4 | 2022 | 55396 | 0.030 |
Why?
| | Adult | 3 | 2022 | 30375 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2021 | 720 | 0.030 |
Why?
| | Disease Progression | 1 | 2022 | 2371 | 0.030 |
Why?
| | Chronic Disease | 1 | 2020 | 1577 | 0.030 |
Why?
| | Models, Molecular | 1 | 2019 | 1368 | 0.030 |
Why?
| | Autoimmunity | 1 | 2019 | 812 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2020 | 3003 | 0.030 |
Why?
| | Cell Proliferation | 1 | 2019 | 2173 | 0.020 |
Why?
| | Prospective Studies | 1 | 2022 | 6195 | 0.020 |
Why?
| | Phenotype | 1 | 2019 | 2784 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 4402 | 0.020 |
Why?
| | Child, Preschool | 1 | 2022 | 9114 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 4595 | 0.020 |
Why?
| | Risk Factors | 1 | 2020 | 8614 | 0.020 |
Why?
| | Signal Transduction | 1 | 2019 | 4501 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2019 | 9049 | 0.020 |
Why?
| | Young Adult | 1 | 2020 | 10444 | 0.020 |
Why?
| | Female | 2 | 2021 | 59325 | 0.010 |
Why?
| | Aged | 1 | 2020 | 18969 | 0.010 |
Why?
| | Adolescent | 1 | 2020 | 17800 | 0.010 |
Why?
| | Middle Aged | 1 | 2020 | 26605 | 0.010 |
Why?
|
|
Eissa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|